// App-Quantinova.ai

336 : Matching-adjusted indirect comparisons of Ixekizumab and Secukinumab using Etanercept and Ustekinumab Bridge Comparators

Researchers

Presenter

  • J. Wu

Principal Investigators

  • D. Saure

  • A. Schacht

  • L. Mallbris

  • S. Wilhelm

  • M. Dossenbach

  • A. Nast

  • R. Warren

Medical Centers

  • University of Manchester, Manchester, United Kingdom

  • Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA

  • Charite Universitätsmedizin, Berlin, GERMANY

  • Eli Lilly and Company, Indianapolis, IN

Locations

  • United Kingdom

  • Germany

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Autoimmune (AI)

Disease

  • Psoriasis

Biomarkers

  • Interleukin 17A

  • TNF Receptor Superfamily Member 1B

Drug/Treatment

  • secukinumab

  • Ustekinumab

  • Etanercept

  • CHS-0214

  • LY2439821

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Active Comparator

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved